Skip to main content

ORIGINAL RESEARCH article

Front. Microbiol.
Sec. Systems Microbiology
Volume 15 - 2024 | doi: 10.3389/fmicb.2024.1447729

Genetically predicted plasma metabolites mediate the casual relationship between gut microbiota and primary immune thrombocytopenia (ITP)

Provisionally accepted
  • Nanjing Drum Tower Hospital, Nanjing, China

The final, formatted version of the article will be published soon.

    Primary immune thrombocytopenia (ITP) is an immune-mediated hematologic disorder characterized by a reduction in platelet count, increasing the risk of bleeding. Recent studies have indicated a close association between alterations in gut microbiota and the development of ITP. However, the mechanisms by which gut microbiota influence the occurrence and progression of ITP through plasma metabolites remain poorly understood. Evidence suggests extensive interactions between gut microbiota and plasma metabolites, implying a potential role for gut microbiota in influencing ITP through alterations in plasma metabolites, which requires further investigation.In this study, summarized GWAS data (including 211 gut microbiota taxa, 1400 plasma metabolites or ratios, and an ITP patient cohort) were retrieved from the MiBioGen and GWAS Catalog databases. Using a two-sample Mendelian randomization (MR) approach, we screened gut microbiota and plasma metabolites potentially causally related to ITP. We further identified plasma metabolites serving as mediators through which gut microbiota affect ITP and calculated the strength of the mediation effect. We also utilized MR Egger and inverse variance weighted methods to detect heterogeneity, and employed MR-Egger and MR-PRESSO methods to assess the presence of pleiotropy.Though two-sample MR analysis, 8 gut microbiota taxa were found to have causal relationships with ITP. After excluding six plasma metabolites with pleiotropy, 39 plasma metabolites were found to be causally related to ITP (P<0.05). 11 plasma metabolites were identified as having causal relationships between gut microbiota and plasma metabolites.Finally, using the delta method, it was calculated that Sphingomyelin levels (8.0%, 95%CI: 0.9% to 11.5%, P=0.047) and Glucose-to-mannose ratio (6.5%, 95%CI: 0.7% to 9.5%, P=0.039) are intermediates for Intestinimonas influencing ITP, while Bilirubin (Z,Z) to etiocholanolone glucuronide ratio (5.6%, 95%CI: 4.7% to 6.9%, P=0.043) is an intermediate for Senegalimassilia influencing ITP.Gut microbiota can influence the development of ITP through changes in plasma metabolites. Sphingomyelin levels, Glucose-to-mannose ratio, and Bilirubin (Z,Z) to etiocholanolone glucuronide ratio are newly discovered intermediates through which gut microbiota influence ITP, providing potential indicators and targets for clinical diagnosis and treatment. This study highlights the intricate relationship between gut microbiota and plasma metabolites in the context of ITP, suggesting new avenues for clinical diagnosis and treatment.

    Keywords: Primary immune thrombocytopenia, Plasma metabolites, Gut Microbiota, Mendelian randomization, mediation analyses

    Received: 03 Jul 2024; Accepted: 07 Oct 2024.

    Copyright: © 2024 Hong, Zhang, Shen, Dong and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xiaoqing Dong, Nanjing Drum Tower Hospital, Nanjing, China
    Bing Chen, Nanjing Drum Tower Hospital, Nanjing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.